BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 20370710)

  • 1. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
    Minkkilä A; Saario S; Nevalainen T
    Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
    Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
    Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into endocannabinoid degradation and its therapeutic potential.
    Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M
    Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
    Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
    Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms.
    Spradley JM; Guindon J; Hohmann AG
    Pharmacol Res; 2010 Sep; 62(3):249-58. PubMed ID: 20416378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid CB
    Leonard MZ; Alapafuja SO; Ji L; Shukla VG; Liu Y; Nikas SP; Makriyannis A; Bergman J; Kangas BD
    J Pharmacol Exp Ther; 2017 Dec; 363(3):314-323. PubMed ID: 28947487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.
    Long JZ; Nomura DK; Vann RE; Walentiny DM; Booker L; Jin X; Burston JJ; Sim-Selley LJ; Lichtman AH; Wiley JL; Cravatt BF
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20270-5. PubMed ID: 19918051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents.
    Wiley JL; Walentiny DM; Wright MJ; Beardsley PM; Burston JJ; Poklis JL; Lichtman AH; Vann RE
    Eur J Pharmacol; 2014 Aug; 737():97-105. PubMed ID: 24858366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation.
    Alvarez-Jaimes LJ; Palmer JA
    Curr Pharm Biotechnol; 2011 Oct; 12(10):1644-59. PubMed ID: 21466449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of alpha/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons.
    Marrs WR; Horne EA; Ortega-Gutierrez S; Cisneros JA; Xu C; Lin YH; Muccioli GG; Lopez-Rodriguez ML; Stella N
    J Biol Chem; 2011 Aug; 286(33):28723-28728. PubMed ID: 21665953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty pain cures.
    Imming P
    Chem Biol; 2007 Dec; 14(12):1311-2. PubMed ID: 18096498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol.
    Ho WS; Randall MD
    Br J Pharmacol; 2007 Mar; 150(5):641-51. PubMed ID: 17245358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets.
    Vandevoorde S; Lambert DM
    Curr Pharm Des; 2005; 11(20):2647-68. PubMed ID: 16101463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain.
    Guindon J; Guijarro A; Piomelli D; Hohmann AG
    Br J Pharmacol; 2011 Aug; 163(7):1464-78. PubMed ID: 21198549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty acid amide hydrolase but not monoacyl glycerol lipase controls cell death induced by the endocannabinoid 2-arachidonoyl glycerol in hepatic cell populations.
    Siegmund SV; Wojtalla A; Schlosser M; Zimmer A; Singer MV
    Biochem Biophys Res Commun; 2013 Jul; 437(1):48-54. PubMed ID: 23806692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.
    Kinsey SG; O'Neal ST; Long JZ; Cravatt BF; Lichtman AH
    Pharmacol Biochem Behav; 2011 Mar; 98(1):21-7. PubMed ID: 21145341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey.
    Lau BK; Drew GM; Mitchell VA; Vaughan CW
    Br J Pharmacol; 2014 Dec; 171(23):5225-36. PubMed ID: 25041240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice.
    Hruba L; Seillier A; Zaki A; Cravatt BF; Lichtman AH; Giuffrida A; McMahon LR
    J Pharmacol Exp Ther; 2015 May; 353(2):261-8. PubMed ID: 25711338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel natural and synthetic ligands of the endocannabinoid system.
    Hanus LO; Mechoulam R
    Curr Med Chem; 2010; 17(14):1341-59. PubMed ID: 20166928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes.
    Saario SM; Savinainen JR; Laitinen JT; Järvinen T; Niemi R
    Biochem Pharmacol; 2004 Apr; 67(7):1381-7. PubMed ID: 15013854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.